Update shared on 31 Oct 2025
Fair value Increased 2.55%Analysts have raised their price target on Tarsus Pharmaceuticals from $78.38 to $80.38, citing expectations for stronger revenue growth and improved profit margins.
Valuation Changes
- Fair Value has increased from $78.38 to $80.38.
- Revenue Growth projections have risen from 42.0% to 44.3%.
- Net Profit Margin estimates have improved from 28.0% to 34.8%.
- Future P/E has declined notably from 20.5x to 16.1x.
- Discount Rate remains unchanged at 6.78%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.